Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05283564 · ClinicalTrials.gov registry record · NA
Study to Evaluate Percussive Ventilation Breathhold to Improve Lung Stereotactic Ablative Radiotherapy
A NA study of Lung Cancer, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05283564: Recruiting NA study of Lung Cancer, sponsored by Stanford University.
NCT05283564 is a NA study of Lung Cancer that is actively recruiting participants, run by Stanford University. The registered enrollment target is 20 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05283564, a NA study of Lung Cancer, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to evaluate and determine the rate of successful administration of Percussive ventilation breathhold (PVB) to allow for more accurate radiotherapy for lung tumors.
Primary Outcome
The rate will be measured as the proportion of healthy volunteers who can be successfully execute the PV breathhold for 5 minutes. In the event of a failure, both investigator and patient will be asked to specify the reason for failure for purposes of failure analysis.
Conditions Studied
Interventions
- OTHER Percussive Ventilation Breathhold SABR (PVB-SABR)
Study Locations (1)
California
- Stanford Cancer Institute - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-11-02 |
| Est. Completion | 2026-09-04 |
| Phase | NA |
What NCT05283564 shows while recruiting
NCT05283564 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Percussive Ventilation Breathhold SABR (PVB-SABR) is the first listed.
NCT05283564 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05283564 about?
NCT05283564 is a clinical study titled "Study to Evaluate Percussive Ventilation Breathhold to Improve Lung Stereotactic Ablative Radiotherapy". The purpose of this research is to evaluate and determine the rate of successful administration of Percussive ventilation breathhold (PVB) to allow for more accurate radiotherapy for lung tumors.
What is the current status of trial NCT05283564?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2022-11-02. Estimated completion is 2026-09-04.
What conditions does trial NCT05283564 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT05283564?
The interventions under investigation include: Percussive Ventilation Breathhold SABR (PVB-SABR) (OTHER).
Who is sponsoring clinical trial NCT05283564?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05283564 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05283564's enrollment target sits among peer trials
20 356th of 409 higher than 46 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI